Robert J. Hickey, PhD
Derek J. Hoelz, PhD
Linda H. Malkas, PhD
Lauren Schnaper, MD
Medical Devices/Medical Diagnostics
TSC MEMBER INSTITUTION(S):
National Institutes of Health
CHANGING THE WAY PATHOLOGISTS SEE CANCER
ABOUT THE COMPANY:
What if a simple tissue or blood test could help doctors quickly tell whether tumors are benign or cancerous? It could mean earlier, less invasive therapies, fewer treatment-related problems and, ultimately, more cancer survivors. This was the challenge tackled by researchers at Indiana University (IU). The product of their research, which was largely funded by the National Institutes of Health and the National Cancer Institute, is CS-Keys. The company has already identified a “biomarker” that distinguishes healthy cells from cancerous cells and can detect the diseased cells when there are only a few present.
The company plans to develop, manufacture, and distribute inexpensive cancer-specific blood and tissue tests that can be used in doctors’ offices. Though research has focused primarily on breast cancer to date, findings can also be applied to other cancers, including those of the esophagus, cervix, and ovaries.
UNIVERSITY-BASED RESEARCH CONNECTION:
CS-Keys was founded to develop and commercialize products based on Indiana University research.
ROLE OF FEDERAL RESEARCH FUNDING:
Approximately $7 million in federal funding from the National Institutes of Health and its National Cancer Institute was directed at IU’s basic science, which formed the foundation of the technology being developed for commercialization by CS-Keys.
Read The Full Report Here